# Denosumab

## Prolia inj 60mg

| TAH Drug Code      | [IPRO6](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPRO6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of osteoporosis in postmenopausal women at high risk of fractures. Treatment of osteoporosis in male patients at high fracture risk, to increase bone mass. Treatment of osteoporosis caused by glucocorticoid use. Treatment of bone loss in male patients undergoing androgen deprivation therapy for non-metastatic prostate cancer who are at high fracture risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | SC, 60 mg every 6 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypocalcemia. Pregnancy & lactation. Severe renal impairment. Hypersensitivity to any component of the product; facial swelling and urticaria have been reported.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Common: Hypercholesterolemia (Osteoporosis, 7.2%), Constipation (Hypercalcemia of malignancy, 21% ; Glucocorticoid-induced osteoporosis, 2.8% ; giant cell tumor of bone, 10% or greater), Diarrhea (10% or greater), Nausea (10% or greater), Toothache (10% or greater), Vomiting (10% or greater), Anemia (Hypercalcemia of malignancy, multiple myeloma, 21-22% ; osteoporosis, 3.3%), Arthralgia (6.7-14.3%), Backache (4.6-34.7%), Musculoskeletal pain (6-10% or greater), Pain in limb (9.9-11.7%), Asthenia (Osteoporosis, postmenopausal, 2.3%; multiple myeloma, bone metastases, breast cancer-related, 13-20%), Headache (3.6-24%), Cystitis (5.9%), Cough (10% or greater), Nasopharyngitis (6.7-10% or greater), Upper respiratory infection (4.9-15%), Fatigue (11-25%) Serious: Endocarditis (0.08%), Cellulitis, Dermatitis, Erysipelas, Rash (2.5-5.1%), Hypercalcemia, Hypocalcemia (1.7-18%), Hypophosphatemia (Bone metastases, 32%; hypercalcemia of malignancy, 76%; bone metastases, giant cell tumor of bone, multiple myeloma (severe), 9.5-21%), Pancreatitis (0.2-0.8%), Anaphylaxis, Hypersensitivity reaction, Infectious disease, Serious (3.9-6%), Fracture of femur, Atypical (0.9%), Osteonecrosis of jaw (Up to 6.6%), Polymyalgia rheumatica, Worsening (2.0%), Dyspnea (21-27%), Pneumonia, Cancer (1.9-4.8%), Substance withdrawal, Rebound effect (3-6%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/denosumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Xgeva inj 120mg

| TAH Drug Code      | [IXGE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IXGE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Multiple myeloma and bone metastasis from solid tumors. Giant cell tumor of bone. Malignant hypercalcemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | SC, bone metastasis associated with solid tumors 120 mg every 4 weeks. Giant cell tumor of bone, hypercalcemia of malignancy 120 mg every 4 weeks, with additional 120 mg doses on days 8 and 15 of first month of therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity. Severe, symptomatic hypocalcaemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | >10%: Cardiovascular: Hypertension (11%) Central nervous system: Fatigue (Xgeva: <45%), headache (Xgeva: 13% to 24%), peripheral edema (5%; Xgeva: 24%) Dermatologic: Dermatitis (4% to 11%), eczema (4% to 11%), skin rash (3% to 11%) Endocrine & metabolic: Hypophosphatemia (Xgeva: 32%), hypocalcemia (2%; Xgeva: 3% to 18%) Gastrointestinal: Nausea (Xgeva: 31%), decreased appetite (Xgeva: 24%), vomiting (Xgeva: 24%), constipation (Xgeva: 21%), diarrhea (Xgeva: 20%) Hematologic & oncologic: Anemia (Xgeva: 21%) Infection: Influenza (11%) Neuromuscular & skeletal: Weakness (Xgeva: ?45%), arthralgia (7% to 14%), limb pain (10% to 12%), back pain (8% to 12%) Respiratory: Dyspnea (Xgeva: 21% to 27%), cough (Xgeva: 15%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/denosumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

